News
ENTX
2.545
-2.86%
-0.075
Entera Bio Strengthens Board with Veteran Biopharma Leader
TipRanks · 7h ago
Weekly Report: what happened at ENTX last week (0928-1002)?
Weekly Report · 1d ago
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Seeking Alpha · 4d ago
Weekly Report: what happened at ENTX last week (0921-0925)?
Weekly Report · 09/28 09:07
Guggenheim Initiates Coverage of Entera Bio with Buy
NASDAQ · 09/25 14:58
Entera Bio Price Target Announced at $11.00/Share by Guggenheim
Dow Jones · 09/25 13:07
Entera Bio Initiated at Buy by Guggenheim
Dow Jones · 09/25 13:07
Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
Benzinga · 09/25 12:57
Guggenheim starts Entera with Buy on N-tab platform potential
TipRanks · 09/25 08:55
Entera Bio initiated with a Buy at Guggenheim
TipRanks · 09/24 22:40
Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX)
TipRanks · 09/23 13:00
Entera Bio initiated with an Outperform at LifeSci Capital
TipRanks · 09/23 11:55
Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating
Benzinga · 09/22 10:36
Entera Bio initiated with an Overweight at Cantor Fitzgerald
TipRanks · 09/22 10:15
Weekly Report: what happened at ENTX last week (0914-0918)?
Weekly Report · 09/21 09:07
Leerink Partners Initiates Coverage of Entera Bio with Outperform Rating
NASDAQ · 09/19 00:12
Entera Bio Price Target Announced at $9.00/Share by Leerink Partners
Dow Jones · 09/18 13:29
Entera Bio Initiated at Outperform by Leerink Partners
Dow Jones · 09/18 13:29
Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9
Benzinga · 09/18 13:19
Analysts’ Top Healthcare Picks: BridgeBio Oncology Therapeutics (BBOT), Entera Bio (ENTX)
TipRanks · 09/18 12:30
More
Webull provides a variety of real-time ENTX stock news. You can receive the latest news about Entera Bio Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ENTX
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.